LEQVIO Drug Patent Profile

Which patents cover Leqvio, and what generic alternatives are available?

Leqvio is a drug marketed by Novartis and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and seventy-six patent family members in thirty-two countries.

The generic ingredient in LEQVIO is inclisiran sodium. One supplier is listed for this compound. Additional details are available on the inclisiran sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Leqvio

Leqvio was eligible for patent challenges on December 22, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 18, 2034. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for LEQVIO

International Patents:	176
US Patents:	10
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	3
Drug Prices:	Drug price information for LEQVIO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LEQVIO
What excipients (inactive ingredients) are in LEQVIO?	LEQVIO excipients list
DailyMed Link:	LEQVIO at DailyMed

See drug prices for LEQVIO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LEQVIO

NDA:

214012

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LEQVIO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Louisville	PHASE4
Monash University	Phase 4
Novartis Pharmaceuticals	Phase 4

See all LEQVIO clinical trials

Paragraph IV (Patent) Challenges for LEQVIO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LEQVIO	Injection	inclisiran sodium	284 mg/1.5 mL	214012	1	2025-12-22

US Patents and Regulatory Information for LEQVIO

LEQVIO is protected by twenty-six US patents and three FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	LEQVIO	inclisiran sodium	SOLUTION;SUBCUTANEOUS	214012-001	Dec 22, 2021		RX	Yes	Yes
Novartis	LEQVIO	inclisiran sodium	SOLUTION;SUBCUTANEOUS	214012-001	Dec 22, 2021		RX	Yes	Yes			Y	Y
Novartis	LEQVIO	inclisiran sodium	SOLUTION;SUBCUTANEOUS	214012-001	Dec 22, 2021		RX	Yes	Yes

Expired US Patents for LEQVIO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	LEQVIO	inclisiran sodium	SOLUTION;SUBCUTANEOUS	214012-001	Dec 22, 2021
Novartis	LEQVIO	inclisiran sodium	SOLUTION;SUBCUTANEOUS	214012-001	Dec 22, 2021
Novartis	LEQVIO	inclisiran sodium	SOLUTION;SUBCUTANEOUS	214012-001	Dec 22, 2021

International Patents for LEQVIO

When does loss-of-exclusivity occur for LEQVIO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Mexico

Netherlands

New Zealand

Norway

Poland

Portugal

San Marino

Serbia

Slovenia

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LEQVIO around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	093835	COMPOSICIONES DE ARNi PARA PCSK9 Y METODOS PARA USARLAS
Argentina	127053	COMPOSICIONES DE ARNI PARA PCSK9 Y MÉTODOS PARA USARLAS
Australia	2013355237	PCSK9 iRNA compositions and methods of use thereof

Supplementary Protection Certificates for LEQVIO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2929031	301107	Netherlands		PRODUCT NAME: INCLISIRAN; REGISTRATION NO/DATE: EU/1/20/1494 20201210
2929031	PA2021510	Lithuania		PRODUCT NAME: INKLISIRANAS; REGISTRATION NO/DATE: EU/1/20/1494 20201209
2929031	2021C/520	Belgium		PRODUCT NAME: INCLISIRAN; AUTHORISATION NUMBER AND DATE: EU/1/20/1494 20201210

LEQVIO (inclisiran) Market Dynamics and Financial Trajectory: Pricing, Uptake, Exclusivity Risk, and Competitive Pressure

Last updated: June 26, 2026

LEQVIO (inclisiran) is a cholesterol-lowering RNAi therapy with two major drivers of commercial performance: reimbursement and uptake in statin-intolerant and high-risk cardiovascular cohorts. Financial trajectory hinges on (1) prescribing inertia for an injectable siRNA, (2) payer coverage rules tied to LDL-C reduction thresholds and guideline positioning, and (3) competitive pressure from PCSK9 monoclonal antibodies and pipeline alternatives targeting LDL lowering.

What is LEQVIO (inclisiran) and how does it make money in the market?

Featured snippet answer: LEQVIO is marketed for lowering LDL-C in patients at high cardiovascular risk, with revenue tied to successful payer adoption, adherence to its twice-yearly dosing schedule, and conversion from PCSK9 mAbs or statin/ezetimibe regimens.

Mechanism and dosing that shape commercial adoption

• Drug class: small interfering RNA (siRNA) targeting PCSK9 mRNA (RNA interference)
• Dosing regimen: typically subcutaneous administration at baseline, then at ~3 months, then every 6 months thereafter (twice-yearly after initiation)
• Commercial implication: a dosing cadence that can reduce “day-to-day” adherence barriers versus daily oral agents, but still requires office-based injection workflows.

Where revenue comes from: high-risk LDL-C reduction

Inclisiran’s addressable market is defined by payers and prescribers as patients who:

• need additional LDL lowering despite standard-of-care, or
• have statin intolerance or inadequate response to maximally tolerated therapy.

Commercial performance is therefore most sensitive to:

• LDL-C criteria embedded in coverage policies
• whether cardiology and lipid clinics treat inclisiran as a default escalation option
• whether payers steer patients toward cheaper first-line agents (generic statins, ezetimibe) before approving inclisiran or requiring prior authorization.

How is LEQVIO priced and reimbursed, and what payer dynamics drive its sales trajectory?

Featured snippet answer: LEQVIO’s sales trajectory depends on negotiated net price, prior authorization friction, and payer policies that can limit use to specific LDL-C thresholds or documented statin intolerance.

Payer coverage levers

Key coverage constraints that tend to determine whether the drug scales:

• Prior authorization (PA): often required
• Step edits: may require failure or intolerance of statin and ezetimibe
• LDL-C thresholds: initial authorization and continuation may be conditioned on LDL response
• Site-of-care rules: outpatient clinic vs home administration can affect cost and throughput

Net pricing vs list pricing

For RNAi drugs, list price is less predictive than:

• rebates and performance-based contracting
• managed-care formulary placement (preferred vs non-preferred)
• tender/strategic purchasing programs in large systems

These factors determine “effective” revenue per patient and whether uptake accelerates or stalls after initial launch.

When does LEQVIO lose exclusivity, and how does that impact long-term revenue?

Featured snippet answer: LEQVIO’s longer-term revenue ceiling is shaped by patent life plus regulatory exclusivity and the likelihood of biosimilar-style competition is not relevant in the typical way it is for biologics; instead, competition risk comes from RNAi/siRNA platform and patent challenges for the active substance, compositions, and delivery/methods.

Exclusivity and patent life: what matters commercially

Revenue durability is determined by:

• active substance and sequence IP (composition-of-matter and related claims)
• delivery system IP (lipid nanoparticle and formulation claims)
• manufacturing and process claims
• method-of-use claims tied to indications and patient selection

Even without a single “hard stop,” the effective exclusivity cliff is when:

• payer leverage increases (more aggressive contracting once perceived patent risk rises)
• generic or “follow-on” RNAi programs become credible enough to trigger price erosion.

What patents protect LEQVIO (inclisiran), and where are the likely infringement/validity pressure points?

Featured snippet answer: The core patent estate typically concentrates on the RNAi sequence targeting PCSK9, the associated compositions (including conjugates or delivery system components), and therapeutic methods for lowering LDL-C. Pressure points concentrate on claim construction around sequence specificity, delivery system equivalents, and formulation/process parameters.

Patent estate categories that drive enforcement strategy

For LEQVIO-type assets, infringement risk clusters around:

1. RNAi target sequence and design
   Claims that require a specific or highly constrained nucleotide sequence and targeting mechanism.
2. Conjugate and chemical modifications
   If claimed, “same function” modifications can still fall outside exact claim scope.
3. Delivery system and formulation
   Lipid nanoparticle composition, ratios, particle characteristics, and manufacturing parameters can be decisive for infringement.
4. Methods of use
   Claims that tie dosing and patient selection to LDL-C targets.

Timing questions investors track

• When could a competitor file a challenge, and what triggers settlement leverage?
• Does the company maintain “evergreening” via formulation, device, or process improvements?

How strong is the patent estate for LEQVIO compared with PCSK9 competitors?

Featured snippet answer: For LDL-C lowering, the competitive comparison is not only clinical efficacy, but also whether the IP perimeter around siRNA delivery and sequence claims is harder to “design around” than monoclonal antibody manufacturing/IP.

Competitive IP geometry

• PCSK9 mAbs: antibody composition and epitopes, plus manufacturing
• Inclisiran (siRNA): sequence targeting plus delivery/formulation and manufacturing

Commercially, a strong estate translates into fewer credible follow-on products that can be contracted at lower prices during exclusivity.

What patent litigation affects LEQVIO, and what outcomes matter for market access?

Featured snippet answer: Patent litigation risk matters for LEQVIO through (1) injunction leverage, (2) settlement-based launch calendars, and (3) payer behavior if “at-risk” generic-style competition becomes credible.

What to watch in litigation outcomes

• Claim validity rulings that narrow the estate and enable early “design-around”
• Settlement agreements that define non-infringement positions or payment-linked timing
• Remedies (injunction vs damages) that determine whether competitors delay or launch

What is the Orange Book status of LEQVIO?

Featured snippet answer: LEQVIO is not evaluated the same way as classic small-molecule drugs in the Orange Book in the way generics are; however, the Orange Book is still relevant to track listed patents tied to the NDA. Market planning should track whether any patents are listed and when they expire.

(If the Orange Book listing details are not present in the source material for this run, no further claims about specific listed patents can be made.)

How does LEQVIO compare with PCSK9 monoclonal antibodies (alirocumab, evolocumab) on adoption and sales momentum?

Featured snippet answer: Inclisiran’s differentiator is the twice-yearly injection schedule, which can lower patient management friction. PCSK9 mAbs can have higher familiarity among specialists but face adherence and dosing burden issues and can compete aggressively on price and access.

Uptake dynamics

Inclisiran adoption depends on:

• cardiologists’ willingness to switch patients from mAbs or from intensified oral regimens
• payer preferences for dosing simplicity vs established reimbursement experience for mAbs
• patient stability and logistics in clinic infusion or injection workflows

Competitive price pressure

The LDL-C market is heavily driven by net price and formulary preference, so sales trajectory for LEQVIO can decelerate if:

• PCSK9 mAbs gain preferential contracting
• payers treat inclisiran as a “last step” rather than a default escalation
• generic or biosimilar-style pricing pressure emerges via competing outcomes-based contracts.

What formulations are protected by LEQVIO patents, and how could that affect “copycat” RNAi products?

Featured snippet answer: Formulation and delivery system patents (typically lipid nanoparticles) are often the most practical barriers to follow-on RNAi products, because manufacturing equivalence can be tightly defined through composition, particle size, and process controls.

Manufacturing and process as an IP moat

Follow-on developers commonly face:

• hard-to-match nanoparticle characteristics
• validated process control parameters
• batch consistency and stability constraints that become linked to claimed methods

Commercially, higher manufacturing complexity can delay scale-up and keep “follow-on” products from quickly eroding net price.

What generic entry risks exist for LEQVIO, and how would that play out commercially?

Featured snippet answer: “Generic entry” in the classic sense is less straightforward for RNAi, so market erosion risk depends on whether competitors can commercialize a legally non-infringing RNAi product that achieves equivalent LDL lowering and secures payer coverage.

Three entry pathways competitors pursue

1. Design-around the sequence claims
2. Design-around delivery/formulation claims
3. Challenge validity and/or infringement through litigation

Commercially, erosion would manifest through:

• new contracting options for payers
• increased rebate pressure on the incumbent
• switching in lipid clinics if clinical and access profiles are comparable.

What FDA pathway and regulatory milestones shaped LEQVIO’s market entry?

Featured snippet answer: LEQVIO reached the market based on FDA approvals supporting LDL-C lowering in defined high-risk populations, with label scope and dosing schedule determining initial payer and prescriber uptake.

Regulatory factors that drive early adoption

• label language that expands eligible populations
• dosing clarity that reduces clinician hesitation
• post-marketing commitments that can affect supply readiness and confidence

How many patients can LEQVIO realistically reach, and what does that imply for revenue ceiling?

Featured snippet answer: The addressable population is the subset of high-risk and treatment-requiring patients who meet payer criteria for LDL lowering beyond standard-of-care. The ceiling is governed by payer approvals, cardiology/lipid clinic adoption rates, and whether patients discontinue mAbs or oral therapy to switch.

Commercial math that dominates investment cases

Sales potential scales with:

• patient start rate per quarter
• persistence to continued 6-month dosing
• net price after rebates
• incremental share gains vs PCSK9 mAbs and ezetimibe intensification

Key revenue risks and upside catalysts for LEQVIO

Revenue risks

• payer restriction tightening (LDL thresholds, step edits, PA delays)
• competitive contracting by PCSK9 mAbs leading to faster share capture
• patent-driven uncertainties that change payer attitudes and contracting behavior
• supply and administration constraints that limit patient throughput

Upside catalysts

• label expansions or guideline alignment that broadens eligibility
• preferred formulary placement through outcomes or budget impact arguments
• increased system-level adoption in cardiology networks
• successful negotiation of net pricing that improves manufacturer economics while sustaining payer access

Key Takeaways

• LEQVIO’s sales trajectory is driven more by payer policy and formulary position than by dosing convenience alone.
• The biggest commercial swing factors are net pricing (rebates, contracts) and uptake rate in high-risk cardiovascular cohorts.
• Long-term revenue depends on patent and formulation/delivery system durability and the credibility/timing of any legally non-infringing RNAi alternatives.
• Competitive pressure is most acute from PCSK9 monoclonal antibodies where net price and formulary steering can rapidly shift share.

FAQs

1. What payer criteria most restrict LEQVIO coverage and delay prior authorization approval?
2. How does LEQVIO persistence (continuation to every-6-month dosing) affect net sales versus initial starts?
3. Do formulary changes for PCSK9 inhibitors translate into faster switching from mAbs to inclisiran?
4. What types of patent claims (sequence, delivery, method-of-use) are most likely to determine litigation outcomes for RNAi LDL therapies?
5. How do net price and outcomes-based contracting typically influence LDL-C therapy uptake across managed care?

References

(No sources were provided in the prompt, and no citations can be generated without verifiable market, financial, FDA, Orange Book, or patent-lifecycle inputs.)

DrugChatter Q&A for LEQVIO

Patent expiry date for leqvio?
When does leqvio patent expire?
How much does leqvio cost?
Leqvio inclisiran cost 2026?
Leqvio medicare reimbursement?